Vesigen Therapeutics was founded by Robert Millman and Quan Lu, PhD at the Harvard T.H. Chan School of Public Health. Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Its patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Investors include Linden Lake, Bayer Leaps and Morningside Venture Investments. www.vesigentx.com

AexeRNA Therapeutics was co-founded by Linden Lake to develop novel mRNA therapeutics and vaccines, leveraging a proprietary high-potency next generation mRNA lipid nanoparticle delivery platform technology. The technology was developed by the late Prof. Mike Buschmann at George Mason University's Volgenau School of Engineering and National Center for Biodefense and Infectious Diseases and Prof. Drew Weisman at the University of Pennsylvania.

AexeRNA was acquired by BioNTech SE (NASDAQ: BNTX) in October 2023.